The median PFS and ORR in the (ziv-)aflibercept arm seem to lie at the upper limit or be higher than those reported in previous trials of docetaxel.16 At 5.2 months, the PFS obtained in this trial is at least a month longer than in the test or control arms of any other phase III trial, other than for the docetaxel and irinotecan combination reported by Pectasides et al.17 The highest response rates previously reported for docetaxel in phase III trials have been less than 15% and typically less than 10%,14,16–19 compared with the 23.3% obtained in evaluable (ziv-)aflibercept-treated patients in this trial (20.6% in randomly assigned patients); the control arm had a response rate consistent with the literature (8.9%).
So 'we are not alone' as the saying goes.
One note, the REGN initial PR was in March and this scientific paper with complete results came out in July, almost 4 months later.
Market Data 
Markets 
AI
